Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

Patients with undetectable MRD at landmark and longitudinal time points had significantly longer disease-free survival than patients who had detectable MRD at those time points. Prolonged ...

At median follow-up, patients in the D-R group showed a higher rate of complete response or better than with lenalidomide alone. The addition of daratumumab to lenalidomide (D-R) for maintenance ...

To Target demand driven minerals in Western Australia.